METLIFE INC's income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Dec 31, 2025 · FY), METLIFE INC reported revenue of $77.1B (+8.6% year on year) and net income of $3.4B (-23.4% year on year).
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Premiums | $49.8B | $44.9B | $44.3B | $49.4B |
| Universal life and investment-type product policy fees | $5.0B | $5.0B | $5.2B | $5.6B |
| Net investment income | $22.6B | $21.3B | $19.9B | $15.9B |
| Other revenues | $2.8B | $2.6B | $2.5B | $2.6B |
| Net investment gains (losses) | ($1.1B) | ($1.2B) | ($2.8B) | ($1.3B) |
| Net derivative gains (losses) | ($1.9B) | ($1.6B) | ($2.1B) | ($2.4B) |
| Total revenues | $77.1B | $71.0B | $66.9B | $69.9B |
| Policyholder benefits and claims | $49.7B | $44.7B | $44.6B | $50.6B |
| Policyholder liability remeasurement (gains) losses | ($150.0M) | ($206.0M) | ($45.0M) | — |
| Market risk benefit remeasurement (gains) losses | ($508.0M) | ($1.1B) | ($994.0M) | — |
| Interest credited to policyholder account balances | $8.9B | $8.3B | $7.9B | $3.7B |
| Policyholder dividends | $553.0M | $595.0M | $622.0M | $701.0M |
| Other expenses | $13.9B | $13.0B | $12.7B | $12.0B |
| Total expenses | $72.4B | $65.4B | $64.7B | $67.0B |
| Income (loss) before provision for income tax | $4.7B | $5.6B | $2.2B | $2.9B |
| Provision for income tax expense (benefit) | $1.3B | $1.2B | $560.0M | $301.0M |
| Net income (loss) | $3.4B | $4.4B | $1.6B | $2.6B |
| Less: Net income (loss) attributable to noncontrolling interests | $24.0M | $18.0M | $24.0M | $19.0M |
| Net income (loss) attributable to MetLife, Inc. | $3.4B | $4.4B | $1.6B | $2.5B |
| Less: Preferred stock dividends | $194.0M | $200.0M | $198.0M | $185.0M |
| Preferred Stock Redemption Premium | $12.0M | — | $0 | $0 |
| Net income (loss) available to MetLife, Inc.’s common shareholders | $3.2B | $4.2B | $1.4B | $2.4B |
| Basic | $4.74 | $5.98 | $1.82 | $2.93 |
| Diluted | $4.71 | $5.94 | $1.81 | $2.91 |
| Line item | Jun 30, 2026 · Q2 | Mar 31, 2026 · Q1 | Sep 30, 2025 · Q3 | Jun 30, 2025 · Q2 |
|---|---|---|---|---|
| Premiums | $11.4B | $12.1B | $10.6B | $10.8B |
| Universal life and investment-type product policy fees | $1.4B | $1.3B | $1.2B | $1.3B |
| Net investment income | $6.7B | $5.4B | $6.1B | $5.7B |
| Other revenues | $845.0M | $852.0M | $724.0M | $679.0M |
| Net investment gains (losses) | ($428.0M) | ($670.0M) | ($325.0M) | ($273.0M) |
| Net derivative gains (losses) | ($772.0M) | $74.0M | ($929.0M) | ($796.0M) |
| Total revenues | $19.2B | $19.1B | $17.4B | $17.3B |
| Policyholder benefits and claims | $11.3B | $11.9B | $10.4B | $10.8B |
| Policyholder liability remeasurement (gains) losses | $18.0M | ($13.0M) | ($159.0M) | $5.0M |
| Market risk benefit remeasurement (gains) losses | ($270.0M) | $120.0M | ($263.0M) | ($277.0M) |
| Interest credited to policyholder account balances | $3.1B | $1.7B | $2.6B | $2.4B |
| Policyholder dividends | $125.0M | $124.0M | $134.0M | $146.0M |
| Other expenses | $3.8B | $3.8B | $3.5B | $3.3B |
| Total expenses | $18.1B | $17.6B | $16.2B | $16.4B |
| Income (loss) before provision for income tax | $1.0B | $1.5B | $1.2B | $980.0M |
| Provision for income tax expense (benefit) | $256.0M | $345.0M | $308.0M | $245.0M |
| Net income (loss) | $779.0M | $1.2B | $902.0M | $735.0M |
| Less: Net income (loss) attributable to noncontrolling interests and redeemable noncontrolling interests | $43.0M | ($23.0M) | $6.0M | $6.0M |
| Net income (loss) attributable to MetLife, Inc. | $736.0M | $1.2B | $896.0M | $729.0M |
| Less: Preferred stock dividends | $31.0M | $45.0M | $66.0M | $31.0M |
| Net income (loss) available to MetLife, Inc.’s common shareholders | $705.0M | $1.1B | $818.0M | $698.0M |
| Comprehensive income (loss) | $1.3B | $43.0M | $3.2B | $1.1B |
| Less: Comprehensive income (loss) attributable to noncontrolling interests and redeemable noncontrolling interests, net of income tax | $31.0M | $1.0M | $8.0M | $7.0M |
| Comprehensive income (loss) attributable to MetLife, Inc. | $1.2B | $42.0M | $3.2B | $1.1B |
| Basic | $1.10 | $1.75 | $1.23 | $1.04 |
| Diluted | $1.09 | $1.74 | $1.22 | $1.03 |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Fixed maturity securities available-for-sale, at estimated fair value (net of allowance for credit loss of $249 and $160, respectively); and amortized cost: $337,201 and $307,421, respectively | $315.9B | $281.0B | $281.4B | $276.8B |
| Equity securities, at estimated fair value | $858.0M | $712.0M | $757.0M | $1.7B |
| Contractholder-directed equity securities and fair value option securities, at estimated fair value (includes $1,751 and $0, respectively, relating to variable interest entities) | $14.0B | $10.7B | $10.3B | $9.7B |
| Mortgage loans (net of allowance for credit loss of $1,193 and $800, respectively; includes $35 and $0, respectively, of mortgage loans held-for-sale) | $84.6B | $89.0B | $92.5B | $83.8B |
| Policy loans | $8.5B | $8.5B | $8.8B | $8.9B |
| Real estate and real estate joint ventures (includes $378 and $378, respectively, under the fair value option; $132 and $65, respectively, of real estate held-for-sale; $302 and $183, respectively, relating to variable interest entities) | $13.4B | $13.3B | $13.3B | $13.1B |
| Other limited partnership interests | $14.9B | $14.4B | $14.8B | $14.4B |
| Short-term investments, principally at estimated fair value | $3.6B | $5.2B | $6.0B | $4.9B |
| Other invested assets (includes $1,698 and $1,851, respectively, of leveraged and direct financing leases; $560 and $424, respectively, relating to variable interest entities) | $16.3B | $18.5B | $18.2B | $20.0B |
| Total investments | $472.2B | $441.4B | $446.1B | $433.3B |
| Cash and cash equivalents, principally at estimated fair value (includes $96 and $0, respectively, relating to variable interest entities) | $22.0B | $20.1B | $20.6B | $20.2B |
| Accrued investment income | $3.7B | $3.5B | $3.6B | $3.4B |
| Premiums, reinsurance and other receivables (includes $0 and $47, respectively, relating to variable interest entities) | $49.1B | $29.8B | $29.0B | $17.5B |
| Market risk benefits, at estimated fair value | $458.0M | $372.0M | $286.0M | — |
| Deferred policy acquisition costs and value of business acquired | $21.1B | $19.6B | $20.2B | $23.0B |
| Current income tax recoverable | $660.0M | $295.0M | $190.0M | $42.0M |
| Deferred income tax asset | $2.6B | $3.0B | $2.6B | $2.8B |
| Goodwill | $9.6B | $8.9B | $9.2B | $9.3B |
| Other assets | $11.8B | $11.1B | $11.1B | $11.0B |
| Separate account assets | $151.9B | $139.5B | $144.6B | $146.0B |
| Total assets | $745.2B | $677.5B | $687.6B | $666.6B |
| Future policy benefits | $208.9B | $193.6B | $196.4B | $204.2B |
| Policyholder account balances | $236.9B | $221.4B | $219.3B | $203.1B |
| Market risk benefits, at estimated fair value | $2.4B | $2.6B | $3.2B | — |
| Other policy-related balances | $20.1B | $18.9B | $19.7B | $19.7B |
| Policyholder dividends payable | $356.0M | $385.0M | $386.0M | $387.0M |
| Payables for collateral under securities loaned and other transactions | $17.1B | $17.1B | $17.5B | $20.9B |
| Short-term debt (includes $117 and $133, respectively, relating to variable interest entities) | $355.0M | $465.0M | $119.0M | $175.0M |
| Long-term debt (includes $28 and $0, respectively, relating to variable interest entities) | $14.5B | $15.1B | $15.5B | $14.6B |
| Collateral financing arrangement | $352.0M | $476.0M | $637.0M | $716.0M |
| Subordinated debt securities | $4.2B | — | — | — |
| Notes Issued by Collateralized Financing Entities | $1.2B | — | — | — |
| Deferred income tax liability | $536.0M | $132.0M | $927.0M | $325.0M |
| Other liabilities (includes $167 and $0, respectively, relating to variable interest entities) | $57.6B | $36.8B | $35.8B | $26.0B |
| Separate account liabilities | $151.9B | $139.5B | $144.6B | $146.0B |
| Total liabilities | $716.2B | $649.8B | $657.3B | $639.3B |
| Redeemable noncontrolling interests | $241.0M | — | — | — |
| Preferred stock, par value $0.01 per share; $2,905 and $3,905, respectively, aggregate liquidation preference | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock, par value $0.01 per share; 3,000,000,000 shares authorized; 1,195,587,190 and 1,194,168,628 shares issued, respectively; 655,333,773 and 689,211,065 shares outstanding, respectively | $12000000.00 | $12000000.00 | $12000000.00 | $12000000.00 |
| Additional paid-in capital | $32.9B | $33.8B | $33.7B | $33.6B |
| Retained earnings | $44.3B | $42.6B | $40.1B | $42.0B |
| Treasury stock, at cost; 540,253,417 and 504,957,563 shares, respectively | -30.7B | -27.8B | -24.6B | -21.5B |
| Accumulated other comprehensive income (loss) | ($18.1B) | ($21.2B) | ($19.2B) | ($27.1B) |
| Total MetLife, Inc.’s stockholders’ equity | $28.4B | $27.4B | $30.0B | $27.0B |
| Noncontrolling interests | $282.0M | $258.0M | $238.0M | $247.0M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Sep 30, 2025 | Jun 30, 2025 |
|---|---|---|---|---|
| Fixed maturity securities available-for-sale, at estimated fair value (net of allowance for credit loss of $224 and $249, respectively); and amortized cost: $347,781 and $337,201, respectively | $322.2B | $316.1B | $304.6B | $298.7B |
| Equity securities, at estimated fair value | $932.0M | $927.0M | $788.0M | $790.0M |
| Contractholder-directed equity securities and fair value option securities, at estimated fair value (includes $1,985 and $1,751, respectively, relating to variable interest entities) | $14.8B | $13.4B | $12.3B | $11.7B |
| Mortgage loans (net of allowance for credit loss of $1,358 and $1,193, respectively; includes $0 and $35, respectively, of mortgage loans held-for-sale) | $82.9B | $83.7B | $85.8B | $86.9B |
| Policy loans | $8.2B | $8.5B | $8.6B | $8.7B |
| Real estate and real estate joint ventures (includes $377 and $378, respectively, under the fair value option; $178 and $132, respectively, of real estate held-for-sale; $431 and $302, respectively, relating to variable interest entities) | $13.1B | $13.4B | $13.9B | $14.0B |
| Other limited partnership interests | $14.8B | $14.5B | $14.7B | $14.3B |
| Short-term investments, principally at estimated fair value | $8.0B | $4.9B | $6.0B | $5.3B |
| Other invested assets (includes $1,637 and $1,698, respectively, of leveraged and direct financing leases; $623 and $560, respectively, relating to variable interest entities) | $17.7B | $17.6B | $16.9B | $16.4B |
| Total investments | $482.6B | $473.1B | $463.7B | $456.7B |
| Cash and cash equivalents, principally at estimated fair value (includes $357 and $96, respectively, relating to variable interest entities) | $19.3B | $22.7B | $20.2B | $22.2B |
| Accrued investment income | $3.8B | $3.8B | $3.8B | $3.5B |
| Premiums, reinsurance and other receivables | $50.6B | $50.3B | $40.3B | $31.5B |
| Market risk benefits, at estimated fair value | $490.0M | $392.0M | $392.0M | $352.0M |
| Deferred policy acquisition costs and value of business acquired | $21.6B | $21.3B | $21.2B | $21.0B |
| Current income tax recoverable | $426.0M | $455.0M | $374.0M | $554.0M |
| Deferred income tax asset | $3.2B | $2.9B | $2.7B | $2.9B |
| Goodwill | $9.5B | $9.6B | $9.1B | $9.1B |
| Other assets | $11.1B | $11.0B | $11.6B | $11.4B |
| Separate account assets | $156.8B | $147.7B | $146.3B | $143.2B |
| Total assets | $759.4B | $743.2B | $719.7B | $702.5B |
| Future policy benefits | $206.2B | $206.6B | $199.2B | $199.0B |
| Policyholder account balances | $245.5B | $239.8B | $235.3B | $232.4B |
| Market risk benefits, at estimated fair value | $2.2B | $2.5B | $2.6B | $2.7B |
| Other policy-related balances | $20.6B | $20.4B | $20.4B | $19.9B |
| Policyholder dividends payable | $349.0M | $337.0M | $369.0M | $367.0M |
| Payables for collateral under securities loaned and other transactions | $18.9B | $18.2B | $17.1B | $17.1B |
| Short-term debt (includes $114 and $117, respectively, relating to variable interest entities) | $460.0M | $404.0M | $378.0M | $379.0M |
| Long-term debt (includes $69 and $28, respectively, relating to variable interest entities) | $14.2B | $14.4B | $15.3B | $15.4B |
| Collateral financing arrangement | $286.0M | $299.0M | $398.0M | $438.0M |
| Subordinated debt securities | $5.1B | $5.1B | $4.2B | $4.2B |
| Notes issued by collateralized financing entities (includes all amounts: under the fair value option; and relating to variable interest entities) | $1.5B | $1.1B | — | — |
| Deferred income tax liability | $311.0M | $382.0M | $574.0M | $430.0M |
| Other liabilities (includes $374 and $167, respectively, relating to variable interest entities) | $59.0B | $58.0B | $48.5B | $39.1B |
| Separate account liabilities | $156.8B | $147.7B | $146.3B | $143.2B |
| Total liabilities | $731.4B | $715.4B | $690.5B | $674.5B |
| Redeemable noncontrolling interests | $220.0M | $206.0M | — | — |
| Preferred stock, par value $0.01 per share; $2,905 aggregate liquidation preference | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock, par value $0.01 per share; 3,000,000,000 shares authorized; 1,196,795,831 and 1,195,587,190 shares issued, respectively; 637,752,080 and 655,333,773 shares outstanding, respectively | $12000000.00 | $12000000.00 | $12000000.00 | $12000000.00 |
| Additional paid-in capital | $32.9B | $32.9B | $32.9B | $33.8B |
| Retained earnings | $45.4B | $45.1B | $43.9B | $43.4B |
| Treasury stock, at cost; 559,043,751 and 540,253,417 shares, respectively | -32.1B | -31.4B | -30.2B | -29.7B |
| Accumulated other comprehensive income (loss) | ($18.7B) | ($19.2B) | ($17.6B) | ($19.9B) |
| Total MetLife, Inc.’s stockholders’ equity | $27.4B | $27.3B | $28.9B | $27.7B |
| Noncontrolling interests | $300.0M | $271.0M | $247.0M | $242.0M |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Net income (loss) | $3.4B | $4.4B | $1.6B | $2.6B |
| Depreciation and amortization expenses | $753.0M | $714.0M | $718.0M | $673.0M |
| Amortization of premiums and accretion of discounts associated with investments, net | ($1.8B) | ($1.5B) | ($1.3B) | ($960.0M) |
| (Gains) losses on investments and from sales of businesses, net | $1.1B | $1.2B | $2.8B | $1.3B |
| (Gains) losses on derivatives, net | $2.3B | $2.7B | $3.3B | $4.3B |
| (Income) loss from equity method investments, net of dividends or distributions | $365.0M | $844.0M | $1.1B | $505.0M |
| Interest credited to policyholder account balances | $9.3B | $8.5B | $8.0B | $3.7B |
| Universal life and investment-type product policy fees | ($4.2B) | ($4.3B) | ($4.0B) | ($4.0B) |
| Change in contractholder-directed equity securities and fair value option securities | ($1.0B) | ($518.0M) | ($539.0M) | $1.7B |
| Change in accrued investment income | ($272.0M) | ($18.0M) | ($194.0M) | ($357.0M) |
| Change in premiums, reinsurance and other receivables | ($27.0M) | $460.0M | ($2.0B) | $256.0M |
| Change in market risk benefits | ($235.0M) | ($782.0M) | ($658.0M) | — |
| Change in deferred policy acquisition costs and value of business acquired, net | ($1.1B) | ($791.0M) | ($660.0M) | ($568.0M) |
| Change in income tax | ($624.0M) | ($484.0M) | ($1.2B) | ($591.0M) |
| Change in other assets | ($555.0M) | $0 | ($124.0M) | $27.0M |
| Change in insurance-related liabilities and policy-related balances | $7.3B | $4.1B | $4.6B | $4.1B |
| Change in other liabilities | $1.9B | ($580.0M) | $2.1B | $341.0M |
| Other, net | $443.0M | $628.0M | $197.0M | $245.0M |
| Net cash provided by (used in) operating activities | $17.1B | $14.6B | $13.7B | $13.2B |
| Sales, maturities and repayments of fixed maturity securities available-for-sale | $59.5B | $55.6B | $58.8B | $88.9B |
| Sales, maturities and repayments of equity securities | $140.0M | $158.0M | $1.0B | $873.0M |
| Sales, maturities and repayments of mortgage loans | $14.6B | $10.4B | $8.5B | $10.8B |
| Sales, maturities and repayments of real estate and real estate joint ventures | $505.0M | $753.0M | $143.0M | $1.1B |
| Sales, maturities and repayments of other limited partnership interests | $1.0B | $1.1B | $915.0M | $1.6B |
| Sales, maturities and repayments of short-term investments | $16.7B | $11.8B | $13.1B | $14.1B |
| Purchases of fixed maturity securities available-for-sale | ($77.6B) | ($65.7B) | ($63.5B) | ($83.0B) |
| Purchases of equity securities | ($67.0M) | ($112.0M) | ($73.0M) | ($1.4B) |
| Purchases of mortgage loans | ($10.8B) | ($8.9B) | ($8.8B) | ($16.4B) |
| Purchases of real estate and real estate joint ventures | ($633.0M) | ($1.0B) | ($1.1B) | ($1.2B) |
| Purchases of other limited partnership interests | ($1.4B) | ($1.4B) | ($1.7B) | ($2.7B) |
| Purchases of short-term investments | ($14.9B) | ($10.9B) | ($14.0B) | ($11.7B) |
| Cash received in connection with freestanding derivatives | $2.5B | $2.3B | $3.1B | $4.5B |
| Cash paid in connection with freestanding derivatives | ($4.5B) | ($4.0B) | ($5.7B) | ($7.8B) |
| Purchases of businesses (net of cash received of $172, $0 and $0, respectively) | ($738.0M) | — | — | ($35.0M) |
| Payments to Acquire Interest in Joint Venture | ($236.0M) | ($40.0M) | $0 | ($240.0M) |
| Net change in policy loans | $21.0M | $106.0M | $34.0M | $104.0M |
| Net change in other invested assets | $362.0M | ($1.4B) | ($1.1B) | ($786.0M) |
| Other, net | ($75.0M) | ($173.0M) | ($143.0M) | ($28.0M) |
| Net cash provided by (used in) investing activities | ($15.6B) | ($11.5B) | ($10.2B) | ($2.6B) |
| Policyholder account balances - deposits | $108.4B | $97.9B | $95.6B | $103.0B |
| Policyholder account balances - withdrawals | ($101.5B) | ($94.9B) | ($90.9B) | ($97.9B) |
| Net change in payables for collateral under securities loaned and other transactions | ($25.0M) | ($244.0M) | ($3.3B) | ($10.7B) |
| Long-term debt issued | $743.0M | $1.6B | $2.0B | $1.0B |
| Long-term debt repaid | ($1.4B) | ($1.8B) | ($1.0B) | ($85.0M) |
| Collateral financing arrangement repaid | ($124.0M) | ($161.0M) | ($79.0M) | ($50.0M) |
| Line item | Jun 30, 2026 · YTD | Mar 31, 2026 · Q1 | Sep 30, 2025 · YTD | Jun 30, 2025 · YTD |
|---|---|---|---|---|
| Net cash provided by (used in) operating activities | $4.9B | $2.7B | $10.0B | $6.4B |
| Sales, maturities and repayments of fixed maturity securities available-for-sale | $40.9B | $19.8B | $42.9B | $27.5B |
| Sales, maturities and repayments of equity securities | $82.0M | $8.0M | $96.0M | $54.0M |
| Sales, maturities and repayments of fair value option securities | $154.0M | — | — | — |
| Sales, maturities and repayments of mortgage loans | $8.2B | $4.2B | $9.2B | $6.4B |
| Sales, maturities and repayments of real estate and real estate joint ventures | $635.0M | $128.0M | $246.0M | $72.0M |
| Sales, maturities and repayments of other limited partnership interests | $682.0M | $437.0M | $669.0M | $504.0M |
| Sales, maturities and repayments of short-term investments | $7.3B | $3.7B | $11.6B | $7.4B |
| Purchases of fixed maturity securities available-for-sale | ($50.4B) | ($23.7B) | ($55.3B) | ($35.5B) |
| Purchases of equity securities | ($173.0M) | ($128.0M) | ($62.0M) | ($48.0M) |
| Payments to Acquire Fair value option securities | ($256.0M) | — | — | — |
| Purchases of mortgage loans | ($7.1B) | ($3.6B) | ($6.3B) | ($4.2B) |
| Purchases of real estate and real estate joint ventures | ($499.0M) | ($215.0M) | ($555.0M) | ($387.0M) |
| Purchases of other limited partnership interests | ($1.0B) | ($381.0M) | ($921.0M) | ($650.0M) |
| Purchases of short-term investments | ($11.1B) | ($4.6B) | ($12.2B) | ($7.4B) |
| Cash received in connection with freestanding derivatives | $1.1B | $601.0M | $2.2B | $1.4B |
| Cash paid in connection with freestanding derivatives | ($2.7B) | ($1.5B) | ($3.2B) | ($2.0B) |
| Net change in policy loans | $269.0M | $54.0M | $14.0M | ($30.0M) |
| Net change in other invested assets | ($398.0M) | ($423.0M) | $454.0M | $557.0M |
| Other, net | ($10.0M) | ($23.0M) | ($87.0M) | ($74.0M) |
| Net cash provided by (used in) investing activities | ($14.3B) | ($5.5B) | ($11.3B) | ($6.3B) |
| Policyholder account balances - deposits | $57.0B | $27.4B | $82.9B | $55.8B |
| Policyholder account balances - withdrawals | ($50.1B) | ($24.1B) | ($77.1B) | ($51.7B) |
| Net change in payables for collateral under securities loaned and other transactions | $1.8B | $1.1B | ($90.0M) | ($118.0M) |
| Long-term debt issued | $65.0M | $61.0M | $743.0M | $713.0M |
| Long-term debt repaid | ($217.0M) | ($53.0M) | ($609.0M) | ($558.0M) |
| Collateral financing arrangement repaid | ($66.0M) | ($53.0M) | ($78.0M) | ($38.0M) |
| Subordinated debt securities issued | $1.0B | $1.0B | $1.0B | $1.0B |
| Derivatives with certain financing elements and other derivative-related transactions, net | ($151.0M) | ($71.0M) | ($132.0M) | ($74.0M) |
| Proceeds from mortgage loan secured financing | $180.0M | $115.0M | $351.0M | $334.0M |
| Repayments of mortgage loan secured financing | ($836.0M) | ($495.0M) | ($877.0M) | ($672.0M) |
| Proceeds from notes issued by collateralized financing entities | $843.0M | — | — | — |
| Repayments of notes issued by collateralized financing entities | ($537.0M) | — | — | — |
| Treasury stock acquired in connection with share repurchases | ($1.5B) | ($755.0M) | ($2.4B) | ($1.9B) |
| Dividends on preferred stock | ($76.0M) | ($45.0M) | ($163.0M) | ($97.0M) |
| Dividends on common stock | ($755.0M) | ($372.0M) | ($1.1B) | ($756.0M) |
| Other, net | $52.0M | ($67.0M) | ($215.0M) | ($231.0M) |
| Net cash provided by (used in) financing activities | $6.8B | $3.6B | $1.2B | $1.7B |
| Effect of change in foreign currency exchange rates on cash and cash equivalents balances | ($95.0M) | ($136.0M) | $309.0M | $295.0M |
| Change in cash and cash equivalents | ($2.7B) | $655.0M | $165.0M | $2.1B |
| Cash and cash equivalents, beginning of period | $22.0B | $22.0B | $20.1B | $20.1B |
| Cash and cash equivalents, end of period | $19.3B | $22.7B | $20.2B | $22.2B |
| Net cash paid for Interest | $531.0M | $243.0M | $754.0M | $507.0M |
| Net cash paid (received) for Income tax | $819.0M | $231.0M | $1.2B | $930.0M |
| Fixed maturity securities available-for-sale received in connection with pension risk transfer transactions | $1.2B | $715.0M | $0 | $0 |
METLIFE INC score and earnings-call analysis · All covered companies
Figures as reported in SEC filings. General information, not investment advice.